Amgen's MariTide phase 2 study shows 'meaningful' reduction in blood sugar, weightJan 12 (Reuters) - Amgen AMGN.O said on Monday a 24-week study of monthly doses of its experimental obesity drug MariTide in people with type 2 diabetes showed "robust and clinically meaningful" reduction in both blood sugar and weight.
In a 52-week extension study, a large majority of participants who received a lower monthly dose or a quarterly dose maintained the weight loss achieved during the initial phase 2 trial, the company said.
(Reporting by Deena Beasley in Los Angeles, Chris Thomas in Mexico City; Editing by Sherry Jacob-Phillips)
((chris.thomas@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments